Professor Bo Norrving
Lund University, Sweden
Bo Norrving is Professor of neurology at Lund University, Sweden. His research activities have focused on stroke epidemiology, stroke syndromes, small vessel disease, ultrasound, neuroimaging, clinical genetics, clinical trials and organisation of stroke services. He was corresponding author of the Swedish Aspirin Low-Dose Trial (SALT) published in The Lancet 1991 as the first trial to demonstrate the benefit of low dose aspirin therapy for the prevention of stroke. The SALT data were also used almost 2 decades later to demonstrate that aspirin had a protective effect on colorectal cancers.
Professor Norrving is chair of the steering committee of SIFAP, the world’s largest study on stroke in the young, and has been involved in a large number of seminal clinical trials. He is member of the Global Burden of Disease group of scientists. He has contributed to >300 articles in peer-reviewed medical journals, and has authored or co-authored several books, including The Oxford Textbook on Stroke and Cerebrovascular Diseases.
Professor Norrving was a European Editor of Stroke 2005 to 2010 followed by a Senior Consulting Editor position until 2015. He is the 1st the Editor-in-Chief of the European Stroke Journal, founded in 2016 by the European Stroke Organization.
Professor Norrving is a founder and current chair of Riskstroke, the world’s 1st national stroke registry, and a stroke register prototype on which many other international registers have been built. He is member of the neurology advisory group, and chairs the cerebrovascular group, for the ICD-11 at the World Health Organisation, in which all cerebrovascular diseases now form a single block (with diseases of the nervous system as primary parent).
Professor Norrving has played an important leadership role in raising the profile of stroke globally. He was President of the World Stroke Organisation (WSO) from 2008 to 2012, and continues as executive officer through to 2016. Under his term as President, WSO underwent a phase of substantial expansion and extension of activities, including involvement with governmental bodies such as the WHO, the UN ECOSOC, and representing stroke at several high level meetings. He chairs the WSO Global Policy Committee, co-chairs the WSO Guidelines and Quality Committee, and co-authored the first WSO global guidelines for stroke under the auspices of the WSO.
Professor John Huguenard
Stanford University School of Medicine, United States
John Huguenard is Professor of Neurology and Neurological Sciences, with additional appointments in Neurosurgery and Molecular and Cellular Physiology, at Stanford School of Medicine. His research and training programme is focused on two central questions relevant to epilepsy: a) What are the cellular and microcircuit factors that lead to seizures, and what are their dynamics? b) With this understanding, how can we then best intervene to prevent or reduce the occurrence of seizures?
Professor Huguenard has extensive leadership and research training experience, having directed the Stanford Epilepsy Training program for postdoctoral fellows for the last 10 years, and the Stanford Neurosciences PhD program from 2006-2013. He is committed to promoting rigorous research – he was an author on the recent NINDS rigor document regarding pre-clinical research (Landis et al, 2012), chaired the Gordon Research Conference on Epilepsy, and has served on both foundation and federal funded research review committees. He is currently chair of the CNNT study section.
Professor Huguenard is currently associate editor of several prominent journals, including Thalamus & Related Systems, Journal of Computational Neuroscience and Experimental Neurology. He has contributed to more than 170 scientific articles, and 15 books and book chapters.
Professor Huguenard is a member of several professional organisations including the American Epilepsy Society and Society for Neuroscience. He is a member of the basic research task force of the Neurobiology Commission, International League against Epilepsy, as well as member of the Professional Advisory Board and Chair of the Review Board of the Epilepsy Foundation.
Professor Richard Siegert
Auckland University of Technology, New Zealand
Richard Siegert is Professor of Psychology and Rehabilitation at AUT University in Auckland. His research interests include psychometrics, outcomes in mental health and rehabilitation, goal setting and applying mindfulness techniques for people with chronic health conditions.
Profesor Siegert has been a lecturer at Victoria University of Wellington, the University of Otago and King’s College London. He is an author on over 110 articles in international journals and an author of two popular textbooks on rehabilitation. His most recent book is Rehabilitation Goal Setting: Theory, Practice and Evidence published recently by CRC Press/Taylor and Francis.
Professor Valery L. Feigin
National Institute for Stroke and Applied Neurosciences, Auckland University of Technology, New Zealand
Valery L. Feigin is Professor of Neurology and Epidemiology, and Director of the National Institute for Stroke and Applied Neurosciences, AUT University, Auckland. He is also an Affiliate Professor at the Department of Global Health, Institute for Health Metrics and Evaluation (IHME), University of Washington, as well as Honorary Professor at the Novosibirsk State Medical University, Russia.
Professor Feigin’s prime research interest is in the epidemiology, prevention and management of stroke and traumatic brain injury. He has published over 280 journal articles, 12 handbooks and 15 book chapters. Professor Feigin is Editor-in-Chief of the journal Neuroepidemiology and a member of the Editorial Boards of 10 international medical journals. He is also a Director on the Board of Directors of the World Stroke Organization and a member of the Advisory Working Group on Stroke for the WHO ICD-11 version.
Professor Feigin is the recipient of many awards, including the McDiarmid Medal of the Royal Society of New Zealand (2015) and World Stroke Organization President’s Award (2014) for his outstanding contribution to stroke research and prevention.
Associate Professor Alice Theadom
National Institute for Stroke and Applied Neurosciences, Auckland University of Technology, New Zealand
Alice Theadom is a NZ Registered Psychologist. She undertook her training in the UK, completing her undergraduate honours degree in Psychology at the University of Essex and MSc in Health Psychology at Surrey University. Alice subsequently completed a period of supervised training in psychology and the Stage 2 Qualification in Health Psychology through the British Psychological Society.
Dr Theadom is Deputy Director of the National Institute for Stroke and Applied Neuroscience and leads the traumatic brain injury and neuromuscular research programmes. She is involved in a wide range of research projects including epidemiological studies, clinical trials, qualitative studies and systematic reviews. Her research interests focus on the epidemiology of neurological illness and injury, application of psychological interventions in rehabilitation, the role and management of sleep in health, individual adjustment to illness and effects of ill health on family/whanau.
Dr Theadom has published many authored and co-authored >70 peer-reviewed journal articles in a range of rehabilitation and psychology journals including; The Lancet Neurology, European Journal of Neurology, Disability and Rehabilitation, Sleep Medicine and the Journal of Psychosomatic Research. Alice coordinates a postgraduate teaching programme in Rehabilitation Psychology at AUT.
Dr Hinemoa Elder
Te Whare Wānanga o Awanuiārangi
Hinemoa Elder is of Ngāti Kuri, Te Aupouri, Te Rarawa and Ngāpuhi descent and is a Fellow of the Royal Australia and New Zealand College of Psychiatrists. Dr Elder is a Professorial Fellow in Indigenous Research at Te Whare Wānanga o Awanuiārangi, and the Eru Pomare Post Doctoral Fellow, Health Research Council of New Zealand. She is also the Māori Strategic Leader for the Centre of Research Excellence (CoRE) for the Ageing Brain.
Dr Elder is an advocate for use of Te Reo Māori and is a graduate of Te Pīnakitanga ki te Reo Kairangi, rangapū tuarima (Te Wānanga o Aotearoa). She has a PhD (Massey University, 2012) that developed theory and a novel recovery approach grounded in Te Ao Māori, for young Māori with traumatic brain injury, their whānau and professionals.
Since 2007 Dr Elder has worked in the area of Youth Forensic Psychiatry in the Waikato, Auckland and Northland regions writing reports for the adult, youth and family courts. Dr Elder also continues to provide neuropsychiatric assessment and treatment working with young people and whānau with traumatic brain injury.
Dr Elder has served on several Ministry of Health reference groups including the expert advisory group of Blueprint II, which articulated the framework for New Zealand Mental Health service funding. She is a deputy psychiatrist member of the NZ Mental Health Review Tribunal, a Specialist Assessor under the Intellectual Disability Compulsory Care and Rehabilitation Act 2003. Dr Elder is also an invited Research Associate of the Person Centred Research Centre, the National Institute for Stroke and Applied Neurosciences and is a member of the Māori Advisory Committee of the Centre for Brain Research, University of Auckland. Dr Elder is a Trustee and Director of Emerge Aoteaora, a national NGO.
Professor Leigh A. Hale
University of Otago, New Zealand
Leigh Hale is the Dean of the School of Physiotherapy / Centre for Health, Activity, and Rehabilitation Research at the University of Otago, New Zealand and the Editor of the New Zealand Journal of Physiotherapy.
She graduated as a physiotherapist from the University of Cape Town (South Africa) and went on to attain her MSc (Neurorehabilitation) and PhD from the University of the Witwatersrand (Wits)(South Africa).
Professor Hale worked as clinical physiotherapist in all areas of physiotherapy before pursuing an academic career. After teaching neurorehabilitation at the Department of Physiotherapy at Wits for ten years, she moved to the University of Otago in 2000. Professor Hale primarily researches in the area of community-based physiotherapeutic rehabilitation for people living with disability and with neurological conditions, such as multiple sclerosis, stroke, and Parkinson’s disease. Her research uses both quantitative and qualitative methodologies and focuses on how physiotherapists can enable people to optimally live healthy and engaging lives
Professor Perminder Sachdev
University of New South Wales, Australia
Perminder Sachdev is Scientia Professor of Neuropsychiatry, Co-Director of the Centre for Healthy Brain Ageing (CHeBA) in the School of Psychiatry, UNSW Medicine, University of New South Wales, Sydney and Clinical Director of the Neuropsychiatric Institute (NPI) at the Prince of Wales Hospital, Sydney, Australia. He is immediate Past-President of the International College of Psychoneuropharmacology (ICGP), a former President of the International Neuropsychiatric Association (INA) and executive member of the International Society for Vascular Cognitive and Behavioural Disorders (VASCOG).
Professor Sachdev has broad research interests, with a major focus on dementia and cognitive ageing, drug-induced movement disorders, neuroimaging and brain stimulation. He leads a programme of research which includes longitudinal cohort studies such as the Sydney Memory and Ageing Study, the Older Australian Twins Study and the Sydney Centenarian Study, and is co-investigator on the PATH Through Life Study. Prof Sachdev has published >500 peer-reviewed journal papers and 5 books, including one for lay readers (The Yipping Tiger and other tales from the neuropsychiatric clinic). He has been cited >22,000 times and his H-index (Google Scholar) is 80. He holds a NHMRC programme grant and a number of other NHMRC and ARC grants, and is chief investigator on the Dementia Collaborative Research Centre grant and the NHMRC Dementia Team Grant.
Professor Sachdev was named the 2010 NSW Scientist of the Year in Biomedical Sciences. In 2011, he was appointed Member of the Order of Australia (AM) for service to medical research in the field of neuropsychiatry, and to professional associations at a national and international level. He received the Dean’s Award for Outstanding Achievement (Academic) at UNSW Australia in 2014. In 2015, he was made a Fellow of the Australian Academy of Health and Medical Sciences.
Dr Richard Roxburgh
Auckland District Health Board, Auckland, New Zealand
Richard Roxburgh is a neurologist at Auckland City Hospital and Senior Lecturer at the University of Auckland. He specializes in seeing patients with neurogenetic disease. The main thrust of his neurogenetic work is in obtaining clinical diagnoses for patients with disease and then organizing appropriate multidisciplinary services to support people with these conditions and optimize their ability to participate in society.
Dr Roxburgh has published over fifty papers in a wide range of neurogenetic subjects from the establishment of the Multiple Sclerosis Severity Score as the gold standard for assessing disease severity in MS to demonstrating that Huntington’s nurses are cost effective in clinical practice and the establishment (with the MDA) of the New Zealand Neuromuscular Disease registry (of which he is principal investigator) and the discovery that half of patients with myotonic dystrophy have the treatable condition called “epiretinal membranes”.
Recently he has been collaborating with Australian researchers in Sydney and at the Broad Institute to obtain genetic diagnoses through Exome sequencing. Which has led to treatable causes being found for three of 28 patients with limb girdle muscular dystrophy, and been an associate investigator on the MD-Prev study which has established the prevalence of genetically determined muscle disease in New Zealand.
Dr Roxburgh is active in partnering with the MDA in NZ writing a column for the quarterly In Touch magazine and acting on the MDA’s research trust. He is also active internationally in the Enroll-HD Huntington’s disease observational study, for which he acts on two committees: one aimed at promoting standards of clinical care and the second in setting standards for clinical publications.